Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$5.52
EPS est.
$5.16
EPS surprise
+6.94%
1-day move
-2.51%
argenx SE reported better-than-expected earnings per share, which is a positive sign for profitability. However, the stock fell by 2.51% despite the EPS beat, likely due to the lack of revenue information and guidance. Investors may be cautious given the uncertainty surrounding future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.52 | $4.19 | +6.94% |
| Revenue | — | $1.1B | — |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
argenx SE is a biotechnology company focused on developing innovative therapies for patients with severe autoimmune diseases and cancer. Operating in the Health Care sector, argenx is recognized for its cutting-edge research and development efforts, which are crucial for advancing treatment options in these challenging medical areas.
Last quarter
In Q4 2025, argenx reported an EPS of $8.02, significantly exceeding analyst expectations. However, the stock experienced a decline of 5.56% the following day, indicating some market skepticism despite the strong earnings.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+236.40%
Avg 1-day reaction
+1.27%
Analysts are generally optimistic about argenx's upcoming earnings, expecting solid performance based on past results. The consensus EPS of $4.19 suggests continued growth, but investor sentiment may hinge on how the company addresses future guidance.
Bull case
If argenx beats EPS expectations and shows strong revenue growth, it could reinforce investor confidence and drive the stock higher, especially given its history of positive surprises.
Bear case
Conversely, if the company misses earnings expectations or fails to provide reassuring guidance, it could lead to a significant sell-off, particularly given the recent stock price volatility.
Key metrics to watch
EPS
$4.19Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$1.1BRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $4.19?
A strong EPS figure could validate the company's growth trajectory and boost investor confidence.
Q2
What guidance will management provide for future revenue growth?
Future guidance is critical for understanding the company's outlook and could significantly impact stock performance.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate argenx's ability to outperform due to its strong pipeline and recent successful trials, which could lead to higher-than-expected revenue.
Supporting evidence
The company's recent track record shows an 88% EPS beat rate, indicating a strong likelihood of exceeding expectations.
Options pricing suggests a significant move, indicating that traders are anticipating volatility that may not align with consensus views.
Key risk
If revenue comes in below $1B, it could undermine confidence in the company's growth trajectory.
Pre-commit to what would confirm each case.
The market is closely watching EPS and revenue guidance to gauge the company's health and growth potential.
Bull confirmed if
An EPS of $4.50 or higher would confirm strong operational performance and growth potential.
Bear confirmed if
An EPS below $3.50 would raise concerns about the company's profitability and future prospects.
What the market is pricing for the move.
Implied Move
±6.41%
Historical Avg
±5.5%
The options market is pricing in a relatively large move, suggesting that traders expect significant volatility around the earnings announcement.
Options are pricing ±6.3% while ARGX has averaged ±5.5% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.5%
30d HV
28.1%
Smart-money positioning from the most recent 13F filings.
Institutional
46.07%
of float
Insider
0.00%
of float
Holders
714
institutions
Top Holders· as of Jun 2026
FMR, LLC
5,231,452 sh · $4.9B
8.36%
4.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If argenx beats expectations, history suggests the stock could rise by around 1.26% on the first trading day post-earnings, confirming positive market sentiment.
In line / cautious
If results are in line with expectations but management is cautious, the stock may experience muted movement as investors weigh future growth prospects.
Miss
If the company misses expectations, history suggests a potential decline of about 0.91%, reflecting market disappointment.
The lines on the call that would change the story.
Price (T.Rowe) Associates Inc
2,678,047 sh · $2.5B
4.28%
-20.6%
Jupiter Topco LLC
2,474,015 sh · $2.3B
3.95%
100.0%
Capital World Investors
2,199,770 sh · $2.0B
3.52%
-2.5%
Artisan Partners Limited Partnership
1,508,778 sh · $1.4B
2.41%
2.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.